144 related articles for article (PubMed ID: 27429559)
1. Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.
Rockenstein E; Desplats P; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Moessler H; Masliah E
J Exp Neurosci; 2015; 9(Suppl 2):131-40. PubMed ID: 27429559
[TBL] [Abstract][Full Text] [Related]
2. Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease.
Rockenstein E; Desplats P; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
Stem Cell Res; 2015 Jul; 15(1):54-67. PubMed ID: 26209890
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
4. Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.
Ozkizilcik A; Sharma A; Muresanu DF; Lafuente JV; Tian ZR; Patnaik R; Mössler H; Sharma HS
Mol Neurobiol; 2018 Jan; 55(1):359-369. PubMed ID: 28875428
[TBL] [Abstract][Full Text] [Related]
5. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
7. Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism.
Goldberg NRS; Caesar J; Park A; Sedgh S; Finogenov G; Masliah E; Davis J; Blurton-Jones M
Stem Cell Reports; 2015 Nov; 5(5):791-804. PubMed ID: 26489892
[TBL] [Abstract][Full Text] [Related]
8. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
[TBL] [Abstract][Full Text] [Related]
9. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.
Yan R; Zhang J; Park HJ; Park ES; Oh S; Zheng H; Junn E; Voronkov M; Stock JB; Mouradian MM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E12053-E12062. PubMed ID: 30509990
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of α-synuclein affects the migration of neural stem cells in mouse subventricular zone.
Tani M; Hayakawa H; Yasuda T; Nihira T; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2010 Nov; 115(4):854-63. PubMed ID: 20374434
[TBL] [Abstract][Full Text] [Related]
11. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
12. Synaptic Regulator α-Synuclein in Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal Neural Stem Cells.
Perez-Villalba A; Sirerol-Piquer MS; Belenguer G; Soriano-Cantón R; Muñoz-Manchado AB; Villadiego J; Alarcón-Arís D; Soria FN; Dehay B; Bezard E; Vila M; Bortolozzi A; Toledo-Aral JJ; Pérez-Sánchez F; Fariñas I
J Neurosci; 2018 Jan; 38(4):814-825. PubMed ID: 29217686
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion.
Yamakado H; Moriwaki Y; Yamasaki N; Miyakawa T; Kurisu J; Uemura K; Inoue H; Takahashi M; Takahashi R
Neurosci Res; 2012 Jun; 73(2):173-7. PubMed ID: 22475625
[TBL] [Abstract][Full Text] [Related]
14. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
15. The role of NUB1 in α-synuclein degradation in Lewy body disease model mice.
Tanji K; Miki Y; Maruyama A; Mori F; Mimura J; Itoh K; Kamitani T; Wakabayashi K
Biochem Biophys Res Commun; 2016 Feb; 470(3):635-642. PubMed ID: 26797281
[TBL] [Abstract][Full Text] [Related]
16. Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.
Mandler M; Rockenstein E; Overk C; Mante M; Florio J; Adame A; Kim C; Santic R; Schneeberger A; Mattner F; Schmidhuber S; Galabova G; Spencer B; Masliah E; Rissman RA
Alzheimers Dement; 2019 Sep; 15(9):1133-1148. PubMed ID: 31378574
[TBL] [Abstract][Full Text] [Related]
17. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.
Kang SS; Zhang Z; Liu X; Manfredsson FP; Benskey MJ; Cao X; Xu J; Sun YE; Ye K
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10773-10778. PubMed ID: 28923922
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-7 Enhances Subventricular Zone Neurogenesis by Inhibiting NLRP3/Caspase-1 Axis in Adult Neural Stem Cells.
Fan Z; Lu M; Qiao C; Zhou Y; Ding JH; Hu G
Mol Neurobiol; 2016 Dec; 53(10):7057-7069. PubMed ID: 26676570
[TBL] [Abstract][Full Text] [Related]
19. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein overexpression increases phospho-protein phosphatase 2A levels via formation of calmodulin/Src complex.
Yang W; Wang X; Duan C; Lu L; Yang H
Neurochem Int; 2013 Sep; 63(3):180-94. PubMed ID: 23796501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
